---
title: 'HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis
  of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN'
date: '2025-02-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39953511/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250215170745&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: The prevalence of HER2-low status varied between the analyzed
  trials. Our results show that survival does not differ between HER2-low and HER2-zero
  tumors in HR + /HER2- cohorts; however, HER2-low status appears to have an inconsistent
  impact on survival in TNBC. Therefore, our findings do not support the characterization
  of HER2-low status as a distinct BC ...'
disable_comments: true
---
CONCLUSION: The prevalence of HER2-low status varied between the analyzed trials. Our results show that survival does not differ between HER2-low and HER2-zero tumors in HR + /HER2- cohorts; however, HER2-low status appears to have an inconsistent impact on survival in TNBC. Therefore, our findings do not support the characterization of HER2-low status as a distinct BC ...